康柏西普辅助玻璃体切除术治疗增生型糖尿病视网膜病变
Practical Journal of Medicine & Pharmacy(2016)
Abstract
糖尿病视网膜病变(diabetic retinopathy,DR)是糖尿病的最常见眼部并发症,增生型糖尿病性视网膜病变(proliferative diabetic retinopathy,PDR)是DR的晚期阶段,常导致失明.研究发现PDR患者玻璃体腔内存在高浓度的血管内皮生长因子(vascular endothelial growth factor,VEGF),与VEGF受体结合后,引起血管内皮细胞增生和血管渗漏,导致视网膜和虹膜新生血管生成.抗VEGF药物眼内注射后可以抑制新生血管和减少血管渗漏,可作为玻璃体切除术前辅助用药.本文回顾性分析笔者所在医院眼科住院35例(35眼)PDR患者,应用抗VEGF药物康柏西普(成都康弘药业,国药准字S20130012)辅助玻璃体切除术进行治疗,取得了较好的临床疗效,现报告如下.
MoreAI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined